Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

UDX also announces the initial closing of its series B financing of approximately $70 million with investors, including Quest Diagnostics Financing to support UDX's pursuit of FDA premarket approval for its colorectal cancer screening blood test CAMBRDIGE, Mass. and SECAUCUS, N.J.

Universal DX Announces Strategic Collaboration with Quest Diagnostics to Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States

Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.

Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service

Quest Mobile™ has 5,000 trained mobile phlebotomists whose reach will extend to 44 states by the end of 2023 SECAUCUS, N.J. , Nov. 9, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced the launch of Quest Mobile™, which makes it easier and more convenient for patients to have a specimen collected for lab testing nationwide.

Quest Diagnostics Launches Mobile Phlebotomy Service, Enabling Convenient At-Home Specimen Collection in the United States

SECAUCUS, N.J. , Oct. 30, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $750 million aggregate principal amount of its 6.400% senior notes due 2033 under Quest Diagnostics' shelf registration statement.

Quest Diagnostics Prices $750 Million of Senior Notes

—Quest to Develop and Market a Lab-developed Test Based on the IP of AlzoSure Predict® in the United States, Extending its Industry-leading Portfolio of Alzheimer's Disease Blood Tests— —Validating Clinical Data Suggests that AlzoSure® Predict's Blood-Based Technology Can Help Identify Whether or Not Individuals Will Progress to Alzheimer's Disease Up to 6 Years Before Diagnosis— MILAN and SECAUCUS, N.J., Oct. 25, 2023 /PRNewswire/ -- Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer's disease (AD), today announced that it has formed a strategic collaboration with Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, designed to improve access to high quality blood tests for evaluating the risk of Alzheimer's disease.

Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure® Predict Alzheimer's Disease Prognostic Technology

Quest Diagnostics Inc. (NYSE:DGX ) Q3 2023 Results Conference Call October 24, 2023 8:30 AM ET Company Participants Shawn Bevec - VP, IR Jim Davis - Chairman, President & CEO Sam Samad - CFO Conference Call Participants Ann Hynes - Mizuho Securities David Westenberg - Piper Sandler Kieran Ryan - Deutsche Bank Elizabeth Anderson - Evercore Kevin Caliendo - UBS Jack Meehan - Nephron Research Patrick Donnelly - Citi Erin Wright - Morgan Stanley Brian Tanquilut - Jefferies Lisa Gill - JP Morgan Operator Welcome to the Quest Diagnostics Third Quarter 2023 Conference Call. At the request of the company, this call is being recorded.

Quest Diagnostics Inc. (DGX) Q3 2023 Earnings Call Transcript

Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.

Quest Diagnostics (DGX) Tops Q3 Earnings, Gross Margin Dips

Although the revenue and EPS for Quest Diagnostics (DGX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Quest Diagnostics (DGX) Q3 Earnings: A Look at Key Metrics

Quest Diagnostics (DGX) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.36 per share a year ago.

Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates

Quest Diagnostics Inc. DGX, -1.84% said Tuesday its third-quarter profit dropped by 12.2% to $225 million, or $1.96 a share, from $256 million, or $2.17 a share, in the year-ago quarter. Adjusted third-quarter profit fell to $2.22 a share from $2.36 a share, and beat the FactSet consensus estimate of $2.19 a share.

Quest Diagnostics profit falls 12%, but beats estimate

Third quarter revenues of $2.30 billion, down 7.7% from 2022 Third quarter reported diluted earnings per share ("EPS") of $1.96, down 9.7% from 2022; and adjusted diluted EPS of $2.22, down 5.9% from 2022 Third quarter base business revenues of $2.27 billion, up 4.6% from 2022 Full year 2023 revenues now expected to be between $9.19 billion and $9.24 billion; reported diluted EPS now expected to be between $7.61 and $7.71; and adjusted diluted EPS expected to be between $8.65 and $8.75 SECAUCUS, N.J. , Oct. 24, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the third quarter ended September 30, 2023.

Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023

Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.

Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?

Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.

Quest Diagnostics (DGX) Gains From New Alliances Amid FX Woes

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Quest Diagnostics (DGX) Q3 Earnings Expected to Decline

Agree Realty

A. O. Smith

Apogee Enterprises

Axis Capital

Caterpillar

Colgate-Palmolive

Camden Property

Erie Indemnity

Evans Bancorp

First of Long Island

Farmers & Merchants Bancorp

First Bancorp

H.B. Fuller

Gladstone Investment

Glacier Bancorp

Graham Holdings

Great Southern Bancorp

Horizon

Intuit

Gladstone Land

Lockheed Martin

Northwest Natural Gas

Bank OZK

Procter & Gamble

Pentair

Republic Bancorp

Royal Gold

Roper Technologies

RPM International

Riverview Bancorp

Shoe Carnival

Star Group

Thor Industries

Tootsie Roll Industries

Toro

WD-40

Williams-Sonoma

Xcel Energy

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Dividend Champion, Contender, And Challenger Highlights: Week Of October 15

Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.

Quest Diagnostics (DGX) to Boost Lab Services With New Pact

Relationship features use of Quest's distributed network of labs to deliver fast testing times in local communities around the United States LITTLETON, Colo. , Oct. 5, 2023 /PRNewswire/ -- Neway, LLC, the U.S. leader in value-based dialysis lab care, today announced a strategic lab services arrangement with Quest Diagnostics (NYSE: DGX) that aims to accelerate dialysis laboratory testing and reduce the laboratory costs of dialysis programs for patients with end-stage renal disease (ESRD).

Neway Forms Lab Services Agreement with Quest Diagnostics to Speed Quality ESRD Testing

SECAUCUS, N.J. , Oct. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2023 financial results on Tuesday, October 24, 2023, before the market opens.

Quest Diagnostics to Release Third Quarter 2023 Financial Results on October 24, 2023

Quest Diagnostics (DGX) and Americares will provide 10 clinics with no-cost diagnostic services for a year to help patients manage chronic disease.

Quest Diagnostics (DGX) to Aid Health Equity With New Pact

SECAUCUS, N.J. , Sept. 8, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Baird 2023 Global Healthcare Conference in New York City on Wednesday, September 13, 2023, at 2:00 p.m.

Quest Diagnostics to Speak at the Baird 2023 Global Healthcare Conference

SECAUCUS, N.J. , Sept. 7, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today released its 2022 Corporate Responsibility Report.

Quest Diagnostics Releases 2022 Corporate Responsibility Report

Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.

Quest Diagnostics' (DGX) AAV Test Gets FDA's Breakthrough Nod

Sarepta Therapeutics

Quest and Sarepta Therapeutics Expand Collaboration to Develop AAV Companion Diagnostics (CDx) for Sarepta's Gene Therapies SECAUCUS, N.J. and CAMBRIDGE, Mass.

Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

Why Is Quest Diagnostics (DGX) Down 0.9% Since Last Earnings Report?

CVS Health

Pfizer

Covid-19 related stocks started spiking again this week. Driven primarily by reports about new variants and increasing spread.

News for Quest Diagnostics Stock (DGX)